NO996274L - CD154-blokkering for terapeutisk protein-inhibitorsyndrom - Google Patents

CD154-blokkering for terapeutisk protein-inhibitorsyndrom

Info

Publication number
NO996274L
NO996274L NO996274A NO996274A NO996274L NO 996274 L NO996274 L NO 996274L NO 996274 A NO996274 A NO 996274A NO 996274 A NO996274 A NO 996274A NO 996274 L NO996274 L NO 996274L
Authority
NO
Norway
Prior art keywords
blockage
protein inhibitor
therapeutic protein
exogenous protein
inhibitor syndrome
Prior art date
Application number
NO996274A
Other languages
English (en)
Norwegian (no)
Other versions
NO996274D0 (no
Inventor
Burt Adelman
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of NO996274D0 publication Critical patent/NO996274D0/no
Publication of NO996274L publication Critical patent/NO996274L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
NO996274A 1997-06-20 1999-12-17 CD154-blokkering for terapeutisk protein-inhibitorsyndrom NO996274L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5027697P 1997-06-20 1997-06-20
PCT/US1998/012773 WO1998058672A1 (en) 1997-06-20 1998-06-19 Cd154 blockade therapy for therapeutic protein inhibitor syndrome

Publications (2)

Publication Number Publication Date
NO996274D0 NO996274D0 (no) 1999-12-17
NO996274L true NO996274L (no) 2000-02-18

Family

ID=21964347

Family Applications (1)

Application Number Title Priority Date Filing Date
NO996274A NO996274L (no) 1997-06-20 1999-12-17 CD154-blokkering for terapeutisk protein-inhibitorsyndrom

Country Status (25)

Country Link
US (1) US20020119151A1 (bg)
EP (1) EP1034001B1 (bg)
JP (1) JP2002504910A (bg)
KR (1) KR100567998B1 (bg)
CN (2) CN1261285A (bg)
AT (1) ATE272408T1 (bg)
AU (1) AU733062B2 (bg)
BG (1) BG64436B1 (bg)
BR (1) BR9810755A (bg)
CA (1) CA2294138A1 (bg)
CZ (1) CZ295805B6 (bg)
DE (1) DE69825473T2 (bg)
EA (1) EA002512B1 (bg)
EE (1) EE9900587A (bg)
ES (1) ES2226152T3 (bg)
HK (1) HK1031825A1 (bg)
HU (1) HUP0002048A3 (bg)
IL (1) IL133305A0 (bg)
IS (1) IS2097B (bg)
NO (1) NO996274L (bg)
NZ (1) NZ502051A (bg)
PT (1) PT1034001E (bg)
SK (1) SK285962B6 (bg)
TR (1) TR199903141T2 (bg)
WO (1) WO1998058672A1 (bg)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ511034A (en) * 1998-09-21 2004-03-26 American Nat Red Cross Methods of downmodulating the immune response to therapeutic proteins
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU2001261585B2 (en) 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
IES20030299A2 (en) * 2002-04-23 2003-10-29 R Stephen Porter Inhibition of platelet aggregation
JP4667383B2 (ja) * 2003-06-13 2011-04-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
ES2353222T3 (es) * 2003-06-13 2011-02-28 Biogen Idec Ma Inc. Anticuerpos anti-cd154 (ligando cd40) aglicosilados y usos de los mismos.
EP2149585B1 (en) 2003-11-04 2013-08-14 Novartis Vaccines and Diagnostics, Inc. Use of antagonistic anti-CD40 monoclonal antibodies
RS20070027A (en) 2004-07-26 2008-11-28 Biogen Idec Ma Inc., Anti-cd154 antibodies
US20070286855A1 (en) * 2004-08-03 2007-12-13 Mayo Foundation For Medical Education And Research Improving treatments
PT1889065E (pt) 2005-05-18 2013-09-27 Novartis Ag Métodos para o diagnóstico e tratamento de doenças tendo uma componente autoimune e/ou inflamatória
JP5290152B2 (ja) 2006-04-21 2013-09-18 ノバルティス アーゲー 拮抗剤抗ｃｄ４０抗体薬学的組成物
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012158789A2 (en) 2011-05-17 2012-11-22 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
BR9807471A (pt) * 1997-01-10 2000-03-21 Biogen Inc Uso do composto anti-cd40l

Also Published As

Publication number Publication date
JP2002504910A (ja) 2002-02-12
HK1031825A1 (en) 2001-06-29
CA2294138A1 (en) 1998-12-30
SK285962B6 (sk) 2007-12-06
IS5274A (is) 1999-11-26
DE69825473T2 (de) 2005-08-04
CZ458899A3 (cs) 2000-04-12
EP1034001A1 (en) 2000-09-13
EA200000059A1 (ru) 2000-08-28
KR100567998B1 (ko) 2006-04-07
CN1651071A (zh) 2005-08-10
EA002512B1 (ru) 2002-06-27
BG64436B1 (en) 2005-02-28
IS2097B (is) 2006-04-12
NO996274D0 (no) 1999-12-17
KR20010013964A (ko) 2001-02-26
HUP0002048A2 (hu) 2000-10-28
EP1034001B1 (en) 2004-08-04
TR199903141T2 (xx) 2000-09-21
PT1034001E (pt) 2004-12-31
WO1998058672A1 (en) 1998-12-30
CZ295805B6 (cs) 2005-11-16
BR9810755A (pt) 2000-08-15
AU733062B2 (en) 2001-05-03
EE9900587A (et) 2000-08-15
HUP0002048A3 (en) 2002-09-30
CN1261285A (zh) 2000-07-26
DE69825473D1 (de) 2004-09-09
ATE272408T1 (de) 2004-08-15
SK180399A3 (en) 2000-06-12
IL133305A0 (en) 2001-04-30
BG104092A (bg) 2000-10-31
NZ502051A (en) 2001-04-27
AU8153698A (en) 1999-01-04
ES2226152T3 (es) 2005-03-16
US20020119151A1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
NO996274D0 (no) CD154-blokkering for terapeutisk protein-inhibitorsyndrom
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
SE9800836D0 (sv) New Compounds
UA66767C2 (uk) Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с
AU2002360592A1 (en) Inhibitors of hepatitis c virus
FI953748A (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
BR9811099A (pt) Inibidores de urocinase
ATE170868T1 (de) Peptid-phosphinyloxymethyl-ketonen als inhibitoren von interleukin-1 beta- konvertierenden enzymen
DK641589A (da) N-aryl-azetidinoner, fremgangsmaade til deres fremstilling og deres anvendelse som elastaseinhibitorer
IS5985A (is) Frumuviðloðunar-bælandi bólgu-eyðandi og ónæmisbælandi efnasambönd
DK1161235T3 (da) Kombinationer til behandling af sygdomme, der involverer angiogenese
AU3864000A (en) Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
WO2000041508A3 (en) Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines
DK0584247T3 (da) Sammensætninger til behandling af kronisk træthedssyndrom
AR026901A1 (es) Peptidos con n-alquilacion que tienen actividad antiangiogenica
HK1045456A1 (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
FI962264A0 (fi) Tulehduksia aiheuttavan sytokiinin muodostumisen inhibiittori, joka käsittää polyprenyylin johdannaisia aktiivisena ainesosana
AU2000265105A1 (en) Methods and compositions for the prevention and treatment of syndrome x
UA94022C2 (ru) Применение ингибитора il-18 для лечения и/или предупреждения алкогольного гепатита
DK0537915T3 (da) N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylaminer som inhibitorer for epinephrin
NO20001846D0 (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer
WO1998018818A3 (en) Hepatitis b inhibitors
WO2004017902A3 (en) Ubiquitin and ubiquitin related molecules for treatment and prevention of harmful activation of the immune system
WO2003064378A3 (de) Verbindungen, die faktor xa-aktivität
PL365687A1 (en) Novel trioxepan compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application